-$0.58 in expected earnings per share for Oak Street Health, Inc. (NYSE:OSH) this quarter
Wall Street brokers expect Oak Street Health, Inc. (NYSE:OSH) to post ($0.58) earnings per share for the current fiscal quarter, Zacks reports. Nine analysts provided earnings estimates for Oak Street Health, with the lowest EPS estimate of $0.67 and the highest estimate of $0.47. Oak Street Health reported earnings of ($0.40) per share in the same quarter last year, which would indicate a negative 45% year-over-year growth rate. The company is expected to release its next earnings report on Tuesday, March 8.
According to Zacks, analysts expect Oak Street Health to report annual earnings of $1.83 per share for the current fiscal year, with EPS estimates ranging from $1.89 to $1.78. For next year, analysts expect the company to post earnings of ($1.92) per share, with EPS estimates ranging from ($2.56) to ($0.98). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts who track Oak Street Health.
Oak Street Health (NYSE:OSH) last released its quarterly results on Monday, November 8. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.02). Oak Street Health had a negative return on equity of 133.13% and a negative net margin of 27.80%. The company posted revenue of $388.70 million in the quarter, compared to $357.53 million expected by analysts. In the same quarter a year earlier, the company posted ($0.15) earnings per share. The company’s quarterly revenue increased by 78.4% compared to the same quarter last year.
A number of analysts have weighed in on the company recently. Morgan Stanley reissued an “equal weight” rating and posted a price target of $33.00 (down from $44.00 previously) on Oak Street Health shares in a Friday, Dec. 17 research report. Cowen downgraded Oak Street Health from an “outperforming” rating to a “market performing” rating and reduced its price target for the company from $48.00 to $25.00 in a research note from the Monday January 10. Piper Sandler lowered her target price on Oak Street Health from $55.00 to $47.00 in a Tuesday, January 11 research report. Zacks Investment Research downgraded Oak Street Health from a “hold” rating to a “sell” rating in a Tuesday, Jan. 18, research report. Finally, Raymond James lowered his target price on Oak Street Health from $60.00 to $35.00 and set an “outperform” rating on the stock in a Tuesday, January 18 report. One research analyst rated the stock with a sell rating, three gave the company a hold rating and ten gave the company’s stock a buy rating. According to MarketBeat.com, the stock currently has an average buy rating and a consensus target price of $54.67.
NYSE OSH shares opened at $16.80 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt ratio of 5.88. The stock has a market capitalization of $4.05 billion, a PE ratio of -10.37 and a beta of 1.14. Oak Street Health has a 12-month low of $14.41 and a 12-month high of $66.31. The stock’s fifty-day simple moving average is $27.05 and its two-hundred-day simple moving average is $40.42.
Separately, CEO Michael T. Pykosz sold 50,000 shares of the company in a trade on Tuesday, November 16. The shares were sold at an average price of $39.76, for a total transaction of $1,988,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available via this link. Additionally, insider Griffin Myers sold 23,383 shares of the company in a trade on Monday, November 15. The shares were sold at an average price of $40.00, for a total transaction of $935,320.00. The disclosure of this sale can be found here. Insiders sold 197,811 shares of the company worth $6,906,289 in the past ninety days. 10.10% of the shares are currently held by insiders.
Several hedge funds have recently changed their positions in the company. Cullen Frost Bankers Inc. purchased a new stake in Oak Street Health stock in Q3 for approximately $28,000. CI Investments Inc. purchased a new stake in shares of Oak Street Health in Q3 worth approximately $28,000. Parkside Financial Bank & Trust purchased a new stake in Oak Street Health during Q3 for approximately $82,000. Captrust Financial Advisors purchased a new stake in Oak Street Health during Q3 for approximately $89,000. Finally, PNC Financial Services Group Inc. increased its stake in Oak Street Health by 27.9% during the third quarter. PNC Financial Services Group Inc. now owns 3,049 shares of the company worth $129,000 after acquiring 665 additional shares in the last quarter. Institutional investors hold 85.67% of the company’s shares.
Company Profile Oak Street Health
Oak Street Health, Inc, together with its subsidiaries, provides patient health services in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2020, it operated 79 centers in Illinois, Indiana, Michigan, Mississippi, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee and Texas.
Further Reading: What is Systematic Risk?
Get a free copy of Zacks’ research report on Oak Street Health (OSH)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Oak Street Health right now?
Before you consider Oak Street Health, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Oak Street Health wasn’t on the list.
Although Oak Street Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here